Fellow Shareholders.
The obvious benefit to help middle age to older men with erection problems stands on its own merits (no pun intended).
There is however at least one other "untapped market" if you like, that could prove very lucrative.
It has become alarmingly clear that large parts of the world are suffering demographically - there just are not nearly enough children born to replace the old people dying off.
But these diminishing figures do not show up in mainstream media and therefor the general consensus is that the world is WAY overpopulated.
The reason for this, and that the counted OVERALL population numbers look “ healthy”, is that medicine and healthcare has improved so dramatically over the last 50 years that it is keeping people alive way longer these days and long after their child bearing years.
But where we DO need people - baby producers in their twenties - the numbers are dramatically dwindling.
On top of this, the people in this category are not particularly interested in having children, largely to do with economical and end-of-the-world pressures but also egoistical self-interests.
To add insult to injury young men report a drastic demise in erectile capacity, most likely due to the same reasons.
So, our product could very likely go from an already favourable position among the enormous customer base of baby boomers with money to burn and a fleeting youth to chase down one more time, to actually become a medical tool for a lost generation of young men who has lost their way and spent way too much time looking at internet porn instead of finding a girlfriend.
- Forums
- ASX - By Stock
- LTP
- Ann: Commercial Update and Regulatory Progress
LTP
ltr pharma limited
Add to My Watchlist
3.45%
!
30.0¢

Ann: Commercial Update and Regulatory Progress, page-62
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
30.0¢ |
Change
0.010(3.45%) |
Mkt cap ! $33.58M |
Open | High | Low | Value | Volume |
29.0¢ | 30.0¢ | 28.5¢ | $105.7K | 362.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 17000 | 29.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
30.0¢ | 407 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 17000 | 0.290 |
1 | 24000 | 0.285 |
2 | 230000 | 0.280 |
7 | 175962 | 0.275 |
10 | 192157 | 0.270 |
Price($) | Vol. | No. |
---|---|---|
0.300 | 407 | 1 |
0.305 | 9760 | 1 |
0.310 | 31582 | 3 |
0.315 | 9460 | 1 |
0.320 | 36858 | 4 |
Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
Featured News
LTP (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online